Nkarta, Inc. (NKTX) vs ProQR Therapeutics N.V. (PRQR)

A side-by-side comparison of Nkarta, Inc. and ProQR Therapeutics N.V. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — NKTX vs PRQR

growth of $100 · dividends reinvested · last 6y
NKTX -94.7% (-38.7%/yr)PRQR -68.1% (-17.4%/yr)PRQR compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $100202120222023202420252026$5$32
NKTX PRQR

NKTX vs PRQR: by the numbers

  • •PRQR is the larger company ($174M vs $168M market cap).
  • •Both run net losses; NKTX's is the smaller (0.00% vs -229.20% net margin).

Metrics side by side

Valuation

MetricNKTXPRQR
P/S ratioN/A8.09
P/B ratio0.681.91

Profitability

MetricNKTXPRQR
Gross margin0.00%83.01%
Operating margin0.00%-275.91%
Net margin0.00%-229.20%
ROE-47.36%-54.27%
ROIC-42.11%-42.61%

Growth (annualized)

MetricNKTXPRQR
Revenue CAGR (5Y)N/A94.34%
Total return CAGR (5Y)-37.28%-26.23%

Frequently asked

How have NKTX and PRQR total returns compared?
Over the past 5 years, NKTX delivered -37.28% and PRQR delivered -26.23% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.